Advances in the etiology of retroperitoneal liposarcoma
10.3760/cma.j.cn112139-20231018-00179
- VernacularTitle:腹膜后脂肪肉瘤病因学研究进展
- Author:
Zhiqing YUAN
1
;
Yingbin LIU
Author Information
1. 上海交通大学医学院附属仁济医院胆胰外科 上海市肿瘤研究所，上海 200127
- Keywords:
Liposarcoma;
Retroperitoneal space;
Genome;
Etiology
- From:
Chinese Journal of Surgery
2024;62(5):472-476
- CountryChina
- Language:Chinese
-
Abstract:
Retroperitoneal liposarcoma is the most common retroperitoneal soft tissue tumor with insidious onset, difficulty in treatment, and easy recurrence. Different subtypes of retroperitoneal liposarcoma differ significantly in pathogenic mechanism, biological behavior, and prognosis. The characteristic molecular event of well-differentiated and dedifferentiated liposarcoma is the amplification of the long arm segment of chromosome 12. The genome of myxoid liposarcoma is characterized by translocations of chromosomes 12 and 16 to form fusion genes. The genomic changes of pleomorphic and myxoid pleomorphic liposarcoma are complex, with multiple chromosomal structural abnormalities. Several signaling pathways related to adipocyte differentiation or lipid metabolism have been found to be involved in the initiation and progression of retroperitoneal liposarcoma. It is unclear whether retroperitoneal liposarcoma originates from naive preadipocytes or dedifferentiated mature adipocytes, and its metabolic characteristics are also poorly understood. The first-line drug treatment for retroperitoneal liposarcoma is anthracycline-based chemotherapy, but patients receive little benefit. Therefore, it is urgent to strengthen the basic research on retroperitoneal liposarcoma to find effective therapeutic targets.
